FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210439968> ?p ?o ?g. }

• W4210439968 endingPage "82" @default.
• W4210439968 startingPage "76" @default.
• W4210439968 abstract "Nonalcoholic steatohepatitis (NASH) is a disease entity with an increasing incidence, with involvement of several metabolic pathways. Various organs, including the liver, kidneys, and the vasculature, are damaged in NASH, indicating the urgent need to develop a standard therapy. Therefore, this study was conducted to investigate the effects of drugs targeting various metabolic pathways and their combinations on a high-fat diet (HFD)-induced NASH medaka model.To investigate the effects of drugs on vascular structures, the NASH animal model was developed using the fli::GFP transgenic medaka fed with HFD at 20 mg/fish daily. The physiological changes, histological changes in the liver, vascular structures in the fin, and serum biochemical markers were evaluated in a time-dependent manner after treatment with selective peroxisome proliferator-activated receptor α modulator (pemafibrate), statin (pitavastatin), sodium-glucose cotransporter 2 inhibitor (tofogliflozin), and their combinations. Furthermore, to determine the mechanisms underlying the effects, whole transcriptome sequencing was conducted using medaka liver samples.Histological analyses revealed significant suppression of fat accumulation and fibrotic changes in the liver after treatment with drugs and their combinations. The expression levels of steatosis- and fibrosis-related genes were modified by the treatments. Moreover, the HFD-induced vascular damages in the fin exhibited milder changes after treatment with the drugs.The effects of treating various metabolic pathways on the medaka body, liver, and vascular structures of the NASH medaka model were evidenced. Moreover, to our knowledge, this study is the first to report whole genome sequence and gene expression evaluation of medaka livers, which could be helpful in clarifying the molecular mechanisms of drugs." @default.
• W4210439968 created "2022-02-08" @default.
• W4210439968 creator A5007989920 @default.
• W4210439968 creator A5012654433 @default.
• W4210439968 creator A5016240303 @default.
• W4210439968 creator A5020441815 @default.
• W4210439968 creator A5021394925 @default.
• W4210439968 creator A5033444655 @default.
• W4210439968 creator A5037848078 @default.
• W4210439968 creator A5040797005 @default.
• W4210439968 creator A5044165971 @default.
• W4210439968 creator A5046634878 @default.
• W4210439968 creator A5049693558 @default.
• W4210439968 creator A5052492261 @default.
• W4210439968 creator A5057054824 @default.
• W4210439968 creator A5086343771 @default.
• W4210439968 creator A5089451069 @default.
• W4210439968 date "2022-03-01" @default.
• W4210439968 modified "2023-10-16" @default.
• W4210439968 title "Effects of a novel selective PPARα modulator, statin, sodium-glucose cotransporter 2 inhibitor, and combinatorial therapy on the liver and vasculature of medaka nonalcoholic steatohepatitis model" @default.
• W4210439968 cites W1615613652 @default.
• W4210439968 cites W2035788161 @default.
• W4210439968 cites W2114348786 @default.
• W4210439968 cites W2140411181 @default.
• W4210439968 cites W2152084424 @default.
• W4210439968 cites W2159286796 @default.
• W4210439968 cites W2217349032 @default.
• W4210439968 cites W2287058651 @default.
• W4210439968 cites W2324915162 @default.
• W4210439968 cites W2520749727 @default.
• W4210439968 cites W2588037944 @default.
• W4210439968 cites W2626446274 @default.
• W4210439968 cites W2742155329 @default.
• W4210439968 cites W2772777089 @default.
• W4210439968 cites W2783528686 @default.
• W4210439968 cites W2896363734 @default.
• W4210439968 cites W2913558988 @default.
• W4210439968 cites W2954048049 @default.
• W4210439968 cites W2976126179 @default.
• W4210439968 cites W3037737059 @default.
• W4210439968 cites W3129584656 @default.
• W4210439968 cites W3147609187 @default.
• W4210439968 cites W3160163020 @default.
• W4210439968 cites W3161045262 @default.
• W4210439968 cites W3162051112 @default.
• W4210439968 cites W3201123873 @default.
• W4210439968 cites W3208173424 @default.
• W4210439968 doi "https://doi.org/10.1016/j.bbrc.2022.01.086" @default.
• W4210439968 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35121372" @default.
• W4210439968 hasPublicationYear "2022" @default.
• W4210439968 type Work @default.
• W4210439968 citedByCount "1" @default.
• W4210439968 countsByYear W42104399682022 @default.
• W4210439968 crossrefType "journal-article" @default.
• W4210439968 hasAuthorship W4210439968A5007989920 @default.
• W4210439968 hasAuthorship W4210439968A5012654433 @default.
• W4210439968 hasAuthorship W4210439968A5016240303 @default.
• W4210439968 hasAuthorship W4210439968A5020441815 @default.
• W4210439968 hasAuthorship W4210439968A5021394925 @default.
• W4210439968 hasAuthorship W4210439968A5033444655 @default.
• W4210439968 hasAuthorship W4210439968A5037848078 @default.
• W4210439968 hasAuthorship W4210439968A5040797005 @default.
• W4210439968 hasAuthorship W4210439968A5044165971 @default.
• W4210439968 hasAuthorship W4210439968A5046634878 @default.
• W4210439968 hasAuthorship W4210439968A5049693558 @default.
• W4210439968 hasAuthorship W4210439968A5052492261 @default.
• W4210439968 hasAuthorship W4210439968A5057054824 @default.
• W4210439968 hasAuthorship W4210439968A5086343771 @default.
• W4210439968 hasAuthorship W4210439968A5089451069 @default.
• W4210439968 hasBestOaLocation W42104399681 @default.
• W4210439968 hasConcept C104317684 @default.
• W4210439968 hasConcept C126322002 @default.
• W4210439968 hasConcept C134018914 @default.
• W4210439968 hasConcept C150194340 @default.
• W4210439968 hasConcept C162317418 @default.
• W4210439968 hasConcept C170493617 @default.
• W4210439968 hasConcept C187345961 @default.
• W4210439968 hasConcept C2776175330 @default.
• W4210439968 hasConcept C2776954865 @default.
• W4210439968 hasConcept C2778772119 @default.
• W4210439968 hasConcept C2779134260 @default.
• W4210439968 hasConcept C2779478299 @default.
• W4210439968 hasConcept C55493867 @default.
• W4210439968 hasConcept C71924100 @default.
• W4210439968 hasConcept C86803240 @default.
• W4210439968 hasConcept C98274493 @default.
• W4210439968 hasConceptScore W4210439968C104317684 @default.
• W4210439968 hasConceptScore W4210439968C126322002 @default.
• W4210439968 hasConceptScore W4210439968C134018914 @default.
• W4210439968 hasConceptScore W4210439968C150194340 @default.
• W4210439968 hasConceptScore W4210439968C162317418 @default.
• W4210439968 hasConceptScore W4210439968C170493617 @default.
• W4210439968 hasConceptScore W4210439968C187345961 @default.
• W4210439968 hasConceptScore W4210439968C2776175330 @default.
• W4210439968 hasConceptScore W4210439968C2776954865 @default.
• W4210439968 hasConceptScore W4210439968C2778772119 @default.
• W4210439968 hasConceptScore W4210439968C2779134260 @default.
• W4210439968 hasConceptScore W4210439968C2779478299 @default.

• next